| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
Hsp90 inhibitors are substances that inhibit the activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. In the present study, we have evaluated the antitumor effects of a novel HSP90 inhibitor, AUY922 for the treatment of lung cancer. AUY922 suppressed cell viability and induced apoptosis in KRas addicted pulmonary adenocarcinoma cells. More, the inhibitor showed antitumor effect in EGFR-TK mutation or EML4-ALK positive lung cancer cells. These results indicate that AUY922 looks to be a promising treatment for non small cell lung cancer including pulmonary adenocarcinoma harboring KRas mutation.
|
